Gustavo A. Angarita, MD, MHS
Biography
Gustavo A. Angarita, MD, specializes in psychiatry with a focus on addiction psychiatry, particularly related to cocaine addiction. He is the director of the Yale Cocaine Research Clinic, inpatient chief of the Clinical Neuroscience Research Unit, and the medical director of the Forensic Drug Diversion Clinic.
Dr. Angarita is dedicated to understanding and treating substance use disorders, aiming to develop effective treatments for cocaine dependence. As an assistant professor of psychiatry at Yale School of Medicine, his research interests include the regulation of cocaine self-administration, validation of remote wireless sensor network technology for detecting cocaine use, and investigating cocaine-induced sleep deficits and their therapeutic effects.
Dr. Angarita received his medical degree from Universidad Militar Nueva Granada. He completed a research fellowship in addictions at Harvard Medical School, followed by a residency in adult psychiatry at Yale School of Medicine. He continued his specialization with a clinical and research fellowship in addictions psychiatry at Harvard Medical School.
Titles
- Assistant Professor of Psychiatry
- Director, Yale Cocaine Research Clinic, Psychiatry
- Associate Director of Clinical Affairs, Clinical Neuroscience Research Unit (CNRU), Psychiatry
- Medical Director, Forensic Drug Diversion Clinic (ForDD)
Education & Training
- MHSYale University School of Medicine (2017)
- Clinical and Research Fellow in Addictions PsychiatryHarvard Medical School (2012)
- Resident in Adult PsychiatryYale University School of Medicine (2010)
- Research Fellowship in AddictionsHarvard Medical School (2006)
- MDUniversidad Militar Nueva Granada (2002)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- AB of Psychiatry & Neurology, Addiction Psychiatry (2012)
- AB of Psychiatry & Neurology, Psychiatry (2011)
- Sadabad F, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, Naganawa M, Gallezot J, Yang Y, Ibrahim W, Pittman B, Cayir S, Radhakrishnan R, Angarita G, Holmes S, Comley R, Carson R, Finnema S, Matuskey D. Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders 2025, 40: 2678-2687. PMID: 41040062, DOI: 10.1002/mds.70041.
- Oliveira D, Costa G, Fontenele R, Córdoba-Delgado M, Funaro M, Campbell C, Fiellin D, Angarita G, De Aquino J. Quantitative sensory testing of pain in persons with opioid use disorder on opioid agonist treatment: a scoping review. Pain Medicine 2025, pnaf132. PMID: 40990827, DOI: 10.1093/pm/pnaf132.
- Oliva H, Pulido-Saavedra A, Paredes-Naveda A, Forselius E, Potenza M, Jegede O, Angarita G. Pharmacotherapies for stimulant use disorder and co-occurring attention deficit hyperactivity disorder: protocol for a systematic review and a meta-analysis. Frontiers In Psychiatry 2025, 16: 1667614. PMID: 40980048, PMCID: PMC12444448, DOI: 10.3389/fpsyt.2025.1667614.
- Virk M, Kitaneh R, Mignosa M, McIntyre S, Nixon T, DeMartini K, O’Malley S, Krystal J, De Feyter H, Angarita G, Mason G, de Graaf R, Kumaragamage C. Metabolism in the human brain following oral consumption of a keto-ester for applications in alcohol use disorder (AUD) with 1H-MRSI. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2025 DOI: 10.58530/2025/0612.
- Zakiniaeiz Y, Hillmer A, Shi H, Pittman B, Nabulsi N, Huang Y, Bonomi R, Matuskey D, Angarita G, McKee S, Cosgrove K. Greater Neuroimmune System Deficit in Women Than Men With Alcohol Use Disorder. Biological Psychiatry 2025, 99: 49-56. PMID: 40412787, PMCID: PMC12353993, DOI: 10.1016/j.biopsych.2025.05.012.
- Raval N, Smart K, Angarita G, Miller R, Huang Y, Krystal J, Carson R, Cosgrove K, O'Malley S, Hillmer A. Acute Alcohol‐Induced Changes Measured With Metabotropic Glutamate Receptor 5 Positron Emission Tomography. Addiction Biology 2025, 30: e70031. PMID: 40309934, PMCID: PMC12044519, DOI: 10.1111/adb.70031.
- Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.
- Angarita G, Mayerson T, Pittman B, Natarajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm. Journal Of Addiction Medicine 2025, 19: 726-729. PMID: 41249021, PMCID: PMC12624222, DOI: 10.1097/adm.0000000000001479.
- Zheng X, Worhunsky P, Liu Q, Guo X, Chen X, Sun H, Zhang J, Toyonaga T, Mecca A, O’Dell R, van Dyck C, Angarita G, Cosgrove K, D’Souza D, Matuskey D, Esterlis I, Carson R, Radhakrishnan R, Liu C. Generating synthetic brain PET images of synaptic density based on MR T1 images using deep learning. EJNMMI Physics 2025, 12: 30. PMID: 40163154, PMCID: PMC11958861, DOI: 10.1186/s40658-025-00744-5.
- Weleff J, Pulido-Saavedra A, Aghaei A, Ing K, Arakelian M, Fontenele R, Nero N, Barnett B, Anand A, Bassir Nia A, Angarita G. The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. Psychiatry Research 2025, 348: 116446. PMID: 40147088, PMCID: PMC12306858, DOI: 10.1016/j.psychres.2025.116446.
- Bassir Nia A, Farahmand Y, Griffith G, Ardavan M, Angarita G, Anand A, Pittenger C. The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder. Current Addiction Reports 2025, 12: 20. DOI: 10.1007/s40429-025-00638-7.
- Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.
- Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M, Potenza M, Angarita G. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature. Expert Opinion On Pharmacotherapy 2024, 26: 133-146. PMID: 39708346, PMCID: PMC11786980, DOI: 10.1080/14656566.2024.2446623.
- Jalilian-Khave L, Kitaneh R, Ysrayl B, Borelli A, Funaro M, Potenza M, Angarita G. Potential roles for vitamin D in preventing and treating impulse control disorders, behavioral addictions, and substance use disorders: A scoping review. Addiction Neuroscience 2024, 14: 100190. PMID: 40083958, PMCID: PMC11902922, DOI: 10.1016/j.addicn.2024.100190.
- Gao H, Magin Z, Fogelman N, Sinha R, Angarita G, Milivojevic V. Stability and Reliability of Repeated Plasma Pregnenolone Levels After Oral Pregnenolone Dosing in Individuals with Cocaine Use Disorder: Pilot Findings. Life 2024, 14: 1483. PMID: 39598281, PMCID: PMC11595496, DOI: 10.3390/life14111483.
- Worhunsky P, Mignosa M, Gallezot J, Pittman B, Nabulsi N, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone R, Carson R, Malison R, Potenza M, Angarita G. Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study. Biological Psychiatry 2024, 97: 651-658. PMID: 39395473, PMCID: PMC11839384, DOI: 10.1016/j.biopsych.2024.09.028.
- Bonomi R, Hillmer A, Woodcock E, Bhatt S, Rusowicz A, Angarita G, Carson R, Davis M, Esterlis I, Nabulsi N, Huang Y, Krystal J, Pietrzak R, Cosgrove K. Microglia-mediated neuroimmune suppression in PTSD is associated with anhedonia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2406005121. PMID: 39172786, PMCID: PMC11363315, DOI: 10.1073/pnas.2406005121.
- Oliva H, Prudente T, Potenza M, Angarita G. M155 Effects of Opioids on the Synaptic Density in Rodents: A Systematic Review and Meta-Analysis. Drug And Alcohol Dependence 2024, 260: 110435. DOI: 10.1016/j.drugalcdep.2023.110435.
- Angarita G, Doernberg M, Gilstad-Hayden K, Yonkers K, Forray A. S10 Provider-Patient Alliance and Trauma Among Pregnant People With Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110121. DOI: 10.1016/j.drugalcdep.2023.110121.
- Angarita G, Mayerson T, Pittman B, Nararajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. ADVANCED CHARACTERIZATION OF ON- ELECTROCARDIOGRAPHIC (ECG) SENSORS’ DISCRIMINATORY POWER IN A HUMAN LABORATORY COCAINE SELF-ADMINISTRATION (SA) PARADIGM. Drug And Alcohol Dependence 2024, 260: 110014. DOI: 10.1016/j.drugalcdep.2023.110014.
- Kohler R, Zhornitsky S, Potenza M, Yip S, Worhunsky P, Angarita G. COCAINE SELF-ADMINISTRATION BEHAVIOR IS ASSOCIATED WITH SUBCORTICAL AND CORTICAL GRAY MATTER IN INDIVIDUALS WITH COCAINE USE DISORDER. Drug And Alcohol Dependence 2024, 260: 110081. DOI: 10.1016/j.drugalcdep.2023.110081.
- Kitaneh R, Jalilian-Khave L, Ysrayl B, Borelli A, Funaro M, Potenza M, Angarita G. The Relationship Between Vitamin D and the Development and Treatment of Attention-Deficit Hyperactivity Disorder: An Overview of Systematic Reviews. Current Behavioral Neuroscience Reports 2024, 11: 164-181. PMID: 40822905, PMCID: PMC12356127, DOI: 10.1007/s40473-024-00278-7.
- Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, PMCID: PMC12179786, DOI: 10.1016/j.neubiorev.2024.105713.
- Oliva H, Prudente T, Nunes E, Cosgrove K, Radhakrishnan R, Potenza M, Angarita G. Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Molecular Psychiatry 2024, 29: 2873-2885. PMID: 38561468, PMCID: PMC11894807, DOI: 10.1038/s41380-024-02519-3.
- Kohler R, Zhornitsky S, Potenza M, Yip S, Worhunsky P, Angarita G. Cocaine self-administration behavior is associated with subcortical and cortical morphometry measures in individuals with cocaine use disorder. The American Journal Of Drug And Alcohol Abuse 2024, 50: 345-356. PMID: 38551365, PMCID: PMC11305926, DOI: 10.1080/00952990.2024.2318585.
- Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.
- Ginapp C, Greenberg N, MacDonald-Gagnon G, Angarita G, Bold K, Potenza M. “Dysregulated not deficit”: A qualitative study on symptomatology of ADHD in young adults. PLOS ONE 2023, 18: e0292721. PMID: 37824501, PMCID: PMC10569543, DOI: 10.1371/journal.pone.0292721.
- Raval N, Angarita G, Matuskey D, Miller R, Drake L, Kapinos M, Nabulsi N, Huang Y, Carson R, O’Malley S, Cosgrove K, Hillmer A. Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography. Molecular Psychiatry 2023, 28: 3384-3390. PMID: 37532797, PMCID: PMC10743097, DOI: 10.1038/s41380-023-02198-6.
- Angarita G, Pittman B, Nararajan A, Mayerson T, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors. Drug And Alcohol Dependence 2023, 250: 110898. PMID: 37523916, PMCID: PMC10905422, DOI: 10.1016/j.drugalcdep.2023.110898.
- Zhornitsky S, Oliva H, Jayne L, Allsop A, Kaye A, Potenza M, Angarita G. Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. Frontiers In Psychiatry 2023, 14: 1197890. PMID: 37435405, PMCID: PMC10331617, DOI: 10.3389/fpsyt.2023.1197890.
- Syed S, Sinha R, Milivojevic V, MacDougall A, LaValle H, Angarita G, Fox H. Hypothalamic‐pituitary‐adrenal and autonomic response to psychological stress in abstinent alcohol use disorder individuals with and without depressive symptomatology. Human Psychopharmacology Clinical And Experimental 2023, 38: e2867. PMID: 37165544, DOI: 10.1002/hup.2867.
- Ginapp C, Greenberg N, Macdonald-Gagnon G, Angarita G, Bold K, Potenza M. The experiences of adults with ADHD in interpersonal relationships and online communities: A qualitative study. SSM - Qualitative Research In Health 2023, 3: 100223. PMID: 37539360, PMCID: PMC10399076, DOI: 10.1016/j.ssmqr.2023.100223.
- Calakos K, Hillmer A, Anderson J, LeVasseur B, Baldassarri S, Angarita G, Matuskey D, Kapinos M, Zheng M, Huang Y, Cosgrove K. Cholinergic system adaptations are associated with cognitive function in people recently abstinent from smoking: a (-)-[18F]flubatine PET study. Neuropsychopharmacology 2023, 48: 683-689. PMID: 36681758, PMCID: PMC9938267, DOI: 10.1038/s41386-023-01535-1.
- Matuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.
- McAlpine L, Lifland B, Check J, Angarita G, Ngo T, Chen P, Dandekar R, Alvarenga B, Browne W, Pleasure S, Wilson M, Spudich S, Farhadian S, Bartley C. Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin. Biological Psychiatry 2022, 93: e25-e29. PMID: 36481066, PMCID: PMC9722219, DOI: 10.1016/j.biopsych.2022.09.007.
- Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review. Current Addiction Reports 2022, 9: 660-670. PMID: 38362235, PMCID: PMC10868722, DOI: 10.1007/s40429-022-00446-3.
- Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 2022, 9: 124-143. DOI: 10.1007/s40473-022-00250-3.
- Hadizadeh H, Flores J, Mayerson T, Worhunsky P, Potenza M, Angarita G. Glutamatergic Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 2022, 9: 101-112. DOI: 10.1007/s40473-022-00252-1.
- Hadizadeh H, Flores J, Nunes E, Mayerson T, Potenza M, Angarita G. Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 2022, 9: 27-46. DOI: 10.1007/s40473-022-00246-z.
- Gullapalli B, Angarita G, Ganesan D, Rahman T. Joint prediction of cocaine craving and euphoria using structured prediction energy networks. 2021, 19-25. DOI: 10.1145/3469266.3469881.
- Gullapalli B, Natarajan A, Angarita G, Malison R, Ganesan D, Rahman T. On-body Sensing of Cocaine Craving, Euphoria and Drug-Seeking Behavior Using Cardiac and Respiratory Signals. Proceedings Of The ACM On Interactive Mobile Wearable And Ubiquitous Technologies 2019, 3: 1-31. DOI: 10.1145/3328917.
- Davis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Carson RE, Krystal JH, Esterlis I. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 11490-11495. PMID: 31085640, PMCID: PMC6561298, DOI: 10.1073/pnas.1818871116.
- Worhunsky P, Matuskey D, Gallezot J, Nabulsi N, Angarita G, Calhoun V, Malison R, Potenza M, Carson R. Regional and network-based alterations in D2/D3 receptor availability in cocaine use disorder. Drug And Alcohol Dependence 2017, 171: e219. DOI: 10.1016/j.drugalcdep.2016.08.598.
- Natarajan A, Angarita G, Gaiser E, Malison R, Ganesan D, Marlin BM. Domain adaptation methods for improving lab-to-field generalization of cocaine detection using wearable ECG. 2016, 2016: 875-885. PMID: 28090605, PMCID: PMC5235327, DOI: 10.1145/2971648.2971666.
- Angarita G, Canavan S, Hodges S, Morgan P. Chapter 21 Sleep and Cocaine. 2016, 220-228. DOI: 10.1016/b978-0-12-800212-4.00021-2.
- Angarita G, Natarajan A, Gaiser E, Parate A, Marlin B, Gueorguieva R, Ganesan D, Malison R. A remote wireless sensor network/electrocardiographic approach to discriminating cocaine use. Drug And Alcohol Dependence 2015, 146: e209. DOI: 10.1016/j.drugalcdep.2014.09.037.
- Natarajan A, Gaiser E, Angarita G, Malison R, Ganesan D, Marlin B. Conditional random fields for morphological analysis of wireless ECG signals. 2014, 2014: 370-379. PMID: 26726321, PMCID: PMC4697765, DOI: 10.1145/2649387.2649414.
- Angarita G, Canavan S, Forselius E, Bessette A, Pittman B, Morgan P. Sleep and clinical outcomes in the placebo arm of a randomized clinical trial of modafinil treatment for cocaine dependence. Drug And Alcohol Dependence 2014, 140: e5. DOI: 10.1016/j.drugalcdep.2014.02.036.
- Angarita GA, Canavan SV, Forselius E, Bessette A, Pittman B, Morgan PT. Abstinence-related changes in sleep during treatment for cocaine dependence. Drug And Alcohol Dependence 2013, 134: 343-347. PMID: 24315572, PMCID: PMC4396819, DOI: 10.1016/j.drugalcdep.2013.11.007.
- Natarajan A, Parate A, Gaiser E, Angarita G, Malison R, Marlin B, Ganesan D. Detecting cocaine use with wearable electrocardiogram sensors. 2013, 123-132. DOI: 10.1145/2493432.2493496.
- Youssef N, Angarita G. Dialectical Behavior Therapy with Suicidal Adolescents. 2011 DOI: 10.3109/10401230802362704.
- Angarita GA, Pittman B, Gueorguieva R, Kalayasiri R, Lynch WJ, Sughondhabirom A, Morgan PT, Malison RT. Regulation of cocaine self-administration in humans: Lack of evidence for loading and maintenance phases. Pharmacology Biochemistry And Behavior 2009, 95: 51-55. PMID: 20005893, PMCID: PMC2824073, DOI: 10.1016/j.pbb.2009.12.005.
- Youssef N, Angarita G. Dialectical Behavior Therapy with Suicidal Adolescents. Annals Of Clinical Psychiatry 2008, 20: 244-245. DOI: 10.1080/10401230802362704.
- Loebl T, Angarita G, Pachas G, Huang K, Lee S, Nino J, Logvinenko T, Culhane M, Evins A. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. The Journal Of Clinical Psychiatry 2008, 69: 480-6. PMID: 18294021, DOI: 10.4088/jcp.v69n0321.
- Angarita G, Reif S, Pirard S, Lee S, Sharon E, Gastfriend D. No-Show for Treatment in Substance Abuse Patients with Comorbid Symptomatology: Validity Results from a Controlled Trial of the ASAM Patient Placement Criteria. Journal Of Addiction Medicine 2007, 1: 79-87. PMID: 21768939, DOI: 10.1097/adm.0b013e3180634c1d.
- Pirard S, Sharon E, Kang S, Angarita G, Gastfriend D. Prevalence of physical and sexual abuse among substance abuse patients and impact on treatment outcomes. Drug And Alcohol Dependence 2004, 78: 57-64. PMID: 15769558, DOI: 10.1016/j.drugalcdep.2004.09.005.
Biography
Gustavo A. Angarita, MD, specializes in psychiatry with a focus on addiction psychiatry, particularly related to cocaine addiction. He is the director of the Yale Cocaine Research Clinic, inpatient chief of the Clinical Neuroscience Research Unit, and the medical director of the Forensic Drug Diversion Clinic.
Dr. Angarita is dedicated to understanding and treating substance use disorders, aiming to develop effective treatments for cocaine dependence. As an assistant professor of psychiatry at Yale School of Medicine, his research interests include the regulation of cocaine self-administration, validation of remote wireless sensor network technology for detecting cocaine use, and investigating cocaine-induced sleep deficits and their therapeutic effects.
Dr. Angarita received his medical degree from Universidad Militar Nueva Granada. He completed a research fellowship in addictions at Harvard Medical School, followed by a residency in adult psychiatry at Yale School of Medicine. He continued his specialization with a clinical and research fellowship in addictions psychiatry at Harvard Medical School.
Titles
- Assistant Professor of Psychiatry
- Director, Yale Cocaine Research Clinic, Psychiatry
- Associate Director of Clinical Affairs, Clinical Neuroscience Research Unit (CNRU), Psychiatry
- Medical Director, Forensic Drug Diversion Clinic (ForDD)
Education & Training
- MHSYale University School of Medicine (2017)
- Clinical and Research Fellow in Addictions PsychiatryHarvard Medical School (2012)
- Resident in Adult PsychiatryYale University School of Medicine (2010)
- Research Fellowship in AddictionsHarvard Medical School (2006)
- MDUniversidad Militar Nueva Granada (2002)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- AB of Psychiatry & Neurology, Addiction Psychiatry (2012)
- AB of Psychiatry & Neurology, Psychiatry (2011)
- Sadabad F, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, Naganawa M, Gallezot J, Yang Y, Ibrahim W, Pittman B, Cayir S, Radhakrishnan R, Angarita G, Holmes S, Comley R, Carson R, Finnema S, Matuskey D. Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders 2025, 40: 2678-2687. PMID: 41040062, DOI: 10.1002/mds.70041.
- Oliveira D, Costa G, Fontenele R, Córdoba-Delgado M, Funaro M, Campbell C, Fiellin D, Angarita G, De Aquino J. Quantitative sensory testing of pain in persons with opioid use disorder on opioid agonist treatment: a scoping review. Pain Medicine 2025, pnaf132. PMID: 40990827, DOI: 10.1093/pm/pnaf132.
- Oliva H, Pulido-Saavedra A, Paredes-Naveda A, Forselius E, Potenza M, Jegede O, Angarita G. Pharmacotherapies for stimulant use disorder and co-occurring attention deficit hyperactivity disorder: protocol for a systematic review and a meta-analysis. Frontiers In Psychiatry 2025, 16: 1667614. PMID: 40980048, PMCID: PMC12444448, DOI: 10.3389/fpsyt.2025.1667614.
- Virk M, Kitaneh R, Mignosa M, McIntyre S, Nixon T, DeMartini K, O’Malley S, Krystal J, De Feyter H, Angarita G, Mason G, de Graaf R, Kumaragamage C. Metabolism in the human brain following oral consumption of a keto-ester for applications in alcohol use disorder (AUD) with 1H-MRSI. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2025 DOI: 10.58530/2025/0612.
- Zakiniaeiz Y, Hillmer A, Shi H, Pittman B, Nabulsi N, Huang Y, Bonomi R, Matuskey D, Angarita G, McKee S, Cosgrove K. Greater Neuroimmune System Deficit in Women Than Men With Alcohol Use Disorder. Biological Psychiatry 2025, 99: 49-56. PMID: 40412787, PMCID: PMC12353993, DOI: 10.1016/j.biopsych.2025.05.012.
- Raval N, Smart K, Angarita G, Miller R, Huang Y, Krystal J, Carson R, Cosgrove K, O'Malley S, Hillmer A. Acute Alcohol‐Induced Changes Measured With Metabotropic Glutamate Receptor 5 Positron Emission Tomography. Addiction Biology 2025, 30: e70031. PMID: 40309934, PMCID: PMC12044519, DOI: 10.1111/adb.70031.
- Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.
- Angarita G, Mayerson T, Pittman B, Natarajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm. Journal Of Addiction Medicine 2025, 19: 726-729. PMID: 41249021, PMCID: PMC12624222, DOI: 10.1097/adm.0000000000001479.
- Zheng X, Worhunsky P, Liu Q, Guo X, Chen X, Sun H, Zhang J, Toyonaga T, Mecca A, O’Dell R, van Dyck C, Angarita G, Cosgrove K, D’Souza D, Matuskey D, Esterlis I, Carson R, Radhakrishnan R, Liu C. Generating synthetic brain PET images of synaptic density based on MR T1 images using deep learning. EJNMMI Physics 2025, 12: 30. PMID: 40163154, PMCID: PMC11958861, DOI: 10.1186/s40658-025-00744-5.
- Weleff J, Pulido-Saavedra A, Aghaei A, Ing K, Arakelian M, Fontenele R, Nero N, Barnett B, Anand A, Bassir Nia A, Angarita G. The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. Psychiatry Research 2025, 348: 116446. PMID: 40147088, PMCID: PMC12306858, DOI: 10.1016/j.psychres.2025.116446.
- Bassir Nia A, Farahmand Y, Griffith G, Ardavan M, Angarita G, Anand A, Pittenger C. The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder. Current Addiction Reports 2025, 12: 20. DOI: 10.1007/s40429-025-00638-7.
- Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.
- Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M, Potenza M, Angarita G. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature. Expert Opinion On Pharmacotherapy 2024, 26: 133-146. PMID: 39708346, PMCID: PMC11786980, DOI: 10.1080/14656566.2024.2446623.
- Jalilian-Khave L, Kitaneh R, Ysrayl B, Borelli A, Funaro M, Potenza M, Angarita G. Potential roles for vitamin D in preventing and treating impulse control disorders, behavioral addictions, and substance use disorders: A scoping review. Addiction Neuroscience 2024, 14: 100190. PMID: 40083958, PMCID: PMC11902922, DOI: 10.1016/j.addicn.2024.100190.
- Gao H, Magin Z, Fogelman N, Sinha R, Angarita G, Milivojevic V. Stability and Reliability of Repeated Plasma Pregnenolone Levels After Oral Pregnenolone Dosing in Individuals with Cocaine Use Disorder: Pilot Findings. Life 2024, 14: 1483. PMID: 39598281, PMCID: PMC11595496, DOI: 10.3390/life14111483.
- Worhunsky P, Mignosa M, Gallezot J, Pittman B, Nabulsi N, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone R, Carson R, Malison R, Potenza M, Angarita G. Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study. Biological Psychiatry 2024, 97: 651-658. PMID: 39395473, PMCID: PMC11839384, DOI: 10.1016/j.biopsych.2024.09.028.
- Bonomi R, Hillmer A, Woodcock E, Bhatt S, Rusowicz A, Angarita G, Carson R, Davis M, Esterlis I, Nabulsi N, Huang Y, Krystal J, Pietrzak R, Cosgrove K. Microglia-mediated neuroimmune suppression in PTSD is associated with anhedonia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2406005121. PMID: 39172786, PMCID: PMC11363315, DOI: 10.1073/pnas.2406005121.
- Oliva H, Prudente T, Potenza M, Angarita G. M155 Effects of Opioids on the Synaptic Density in Rodents: A Systematic Review and Meta-Analysis. Drug And Alcohol Dependence 2024, 260: 110435. DOI: 10.1016/j.drugalcdep.2023.110435.
- Angarita G, Doernberg M, Gilstad-Hayden K, Yonkers K, Forray A. S10 Provider-Patient Alliance and Trauma Among Pregnant People With Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110121. DOI: 10.1016/j.drugalcdep.2023.110121.
- Angarita G, Mayerson T, Pittman B, Nararajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. ADVANCED CHARACTERIZATION OF ON- ELECTROCARDIOGRAPHIC (ECG) SENSORS’ DISCRIMINATORY POWER IN A HUMAN LABORATORY COCAINE SELF-ADMINISTRATION (SA) PARADIGM. Drug And Alcohol Dependence 2024, 260: 110014. DOI: 10.1016/j.drugalcdep.2023.110014.
- Kohler R, Zhornitsky S, Potenza M, Yip S, Worhunsky P, Angarita G. COCAINE SELF-ADMINISTRATION BEHAVIOR IS ASSOCIATED WITH SUBCORTICAL AND CORTICAL GRAY MATTER IN INDIVIDUALS WITH COCAINE USE DISORDER. Drug And Alcohol Dependence 2024, 260: 110081. DOI: 10.1016/j.drugalcdep.2023.110081.
- Kitaneh R, Jalilian-Khave L, Ysrayl B, Borelli A, Funaro M, Potenza M, Angarita G. The Relationship Between Vitamin D and the Development and Treatment of Attention-Deficit Hyperactivity Disorder: An Overview of Systematic Reviews. Current Behavioral Neuroscience Reports 2024, 11: 164-181. PMID: 40822905, PMCID: PMC12356127, DOI: 10.1007/s40473-024-00278-7.
- Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, PMCID: PMC12179786, DOI: 10.1016/j.neubiorev.2024.105713.
- Oliva H, Prudente T, Nunes E, Cosgrove K, Radhakrishnan R, Potenza M, Angarita G. Substance use and spine density: a systematic review and meta-analysis of preclinical studies. Molecular Psychiatry 2024, 29: 2873-2885. PMID: 38561468, PMCID: PMC11894807, DOI: 10.1038/s41380-024-02519-3.
- Kohler R, Zhornitsky S, Potenza M, Yip S, Worhunsky P, Angarita G. Cocaine self-administration behavior is associated with subcortical and cortical morphometry measures in individuals with cocaine use disorder. The American Journal Of Drug And Alcohol Abuse 2024, 50: 345-356. PMID: 38551365, PMCID: PMC11305926, DOI: 10.1080/00952990.2024.2318585.
- Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.
- Ginapp C, Greenberg N, MacDonald-Gagnon G, Angarita G, Bold K, Potenza M. “Dysregulated not deficit”: A qualitative study on symptomatology of ADHD in young adults. PLOS ONE 2023, 18: e0292721. PMID: 37824501, PMCID: PMC10569543, DOI: 10.1371/journal.pone.0292721.
- Raval N, Angarita G, Matuskey D, Miller R, Drake L, Kapinos M, Nabulsi N, Huang Y, Carson R, O’Malley S, Cosgrove K, Hillmer A. Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography. Molecular Psychiatry 2023, 28: 3384-3390. PMID: 37532797, PMCID: PMC10743097, DOI: 10.1038/s41380-023-02198-6.
- Angarita G, Pittman B, Nararajan A, Mayerson T, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors. Drug And Alcohol Dependence 2023, 250: 110898. PMID: 37523916, PMCID: PMC10905422, DOI: 10.1016/j.drugalcdep.2023.110898.
- Zhornitsky S, Oliva H, Jayne L, Allsop A, Kaye A, Potenza M, Angarita G. Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. Frontiers In Psychiatry 2023, 14: 1197890. PMID: 37435405, PMCID: PMC10331617, DOI: 10.3389/fpsyt.2023.1197890.
- Syed S, Sinha R, Milivojevic V, MacDougall A, LaValle H, Angarita G, Fox H. Hypothalamic‐pituitary‐adrenal and autonomic response to psychological stress in abstinent alcohol use disorder individuals with and without depressive symptomatology. Human Psychopharmacology Clinical And Experimental 2023, 38: e2867. PMID: 37165544, DOI: 10.1002/hup.2867.
- Ginapp C, Greenberg N, Macdonald-Gagnon G, Angarita G, Bold K, Potenza M. The experiences of adults with ADHD in interpersonal relationships and online communities: A qualitative study. SSM - Qualitative Research In Health 2023, 3: 100223. PMID: 37539360, PMCID: PMC10399076, DOI: 10.1016/j.ssmqr.2023.100223.
- Calakos K, Hillmer A, Anderson J, LeVasseur B, Baldassarri S, Angarita G, Matuskey D, Kapinos M, Zheng M, Huang Y, Cosgrove K. Cholinergic system adaptations are associated with cognitive function in people recently abstinent from smoking: a (-)-[18F]flubatine PET study. Neuropsychopharmacology 2023, 48: 683-689. PMID: 36681758, PMCID: PMC9938267, DOI: 10.1038/s41386-023-01535-1.
- Matuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.
- McAlpine L, Lifland B, Check J, Angarita G, Ngo T, Chen P, Dandekar R, Alvarenga B, Browne W, Pleasure S, Wilson M, Spudich S, Farhadian S, Bartley C. Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin. Biological Psychiatry 2022, 93: e25-e29. PMID: 36481066, PMCID: PMC9722219, DOI: 10.1016/j.biopsych.2022.09.007.
- Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review. Current Addiction Reports 2022, 9: 660-670. PMID: 38362235, PMCID: PMC10868722, DOI: 10.1007/s40429-022-00446-3.
- Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 2022, 9: 124-143. DOI: 10.1007/s40473-022-00250-3.
- Hadizadeh H, Flores J, Mayerson T, Worhunsky P, Potenza M, Angarita G. Glutamatergic Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 2022, 9: 101-112. DOI: 10.1007/s40473-022-00252-1.
- Hadizadeh H, Flores J, Nunes E, Mayerson T, Potenza M, Angarita G. Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 2022, 9: 27-46. DOI: 10.1007/s40473-022-00246-z.
- Gullapalli B, Angarita G, Ganesan D, Rahman T. Joint prediction of cocaine craving and euphoria using structured prediction energy networks. 2021, 19-25. DOI: 10.1145/3469266.3469881.
- Gullapalli B, Natarajan A, Angarita G, Malison R, Ganesan D, Rahman T. On-body Sensing of Cocaine Craving, Euphoria and Drug-Seeking Behavior Using Cardiac and Respiratory Signals. Proceedings Of The ACM On Interactive Mobile Wearable And Ubiquitous Technologies 2019, 3: 1-31. DOI: 10.1145/3328917.
- Davis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Carson RE, Krystal JH, Esterlis I. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 11490-11495. PMID: 31085640, PMCID: PMC6561298, DOI: 10.1073/pnas.1818871116.
- Worhunsky P, Matuskey D, Gallezot J, Nabulsi N, Angarita G, Calhoun V, Malison R, Potenza M, Carson R. Regional and network-based alterations in D2/D3 receptor availability in cocaine use disorder. Drug And Alcohol Dependence 2017, 171: e219. DOI: 10.1016/j.drugalcdep.2016.08.598.
- Natarajan A, Angarita G, Gaiser E, Malison R, Ganesan D, Marlin BM. Domain adaptation methods for improving lab-to-field generalization of cocaine detection using wearable ECG. 2016, 2016: 875-885. PMID: 28090605, PMCID: PMC5235327, DOI: 10.1145/2971648.2971666.
- Angarita G, Canavan S, Hodges S, Morgan P. Chapter 21 Sleep and Cocaine. 2016, 220-228. DOI: 10.1016/b978-0-12-800212-4.00021-2.
- Angarita G, Natarajan A, Gaiser E, Parate A, Marlin B, Gueorguieva R, Ganesan D, Malison R. A remote wireless sensor network/electrocardiographic approach to discriminating cocaine use. Drug And Alcohol Dependence 2015, 146: e209. DOI: 10.1016/j.drugalcdep.2014.09.037.
- Natarajan A, Gaiser E, Angarita G, Malison R, Ganesan D, Marlin B. Conditional random fields for morphological analysis of wireless ECG signals. 2014, 2014: 370-379. PMID: 26726321, PMCID: PMC4697765, DOI: 10.1145/2649387.2649414.
- Angarita G, Canavan S, Forselius E, Bessette A, Pittman B, Morgan P. Sleep and clinical outcomes in the placebo arm of a randomized clinical trial of modafinil treatment for cocaine dependence. Drug And Alcohol Dependence 2014, 140: e5. DOI: 10.1016/j.drugalcdep.2014.02.036.
- Angarita GA, Canavan SV, Forselius E, Bessette A, Pittman B, Morgan PT. Abstinence-related changes in sleep during treatment for cocaine dependence. Drug And Alcohol Dependence 2013, 134: 343-347. PMID: 24315572, PMCID: PMC4396819, DOI: 10.1016/j.drugalcdep.2013.11.007.
- Natarajan A, Parate A, Gaiser E, Angarita G, Malison R, Marlin B, Ganesan D. Detecting cocaine use with wearable electrocardiogram sensors. 2013, 123-132. DOI: 10.1145/2493432.2493496.
- Youssef N, Angarita G. Dialectical Behavior Therapy with Suicidal Adolescents. 2011 DOI: 10.3109/10401230802362704.
- Angarita GA, Pittman B, Gueorguieva R, Kalayasiri R, Lynch WJ, Sughondhabirom A, Morgan PT, Malison RT. Regulation of cocaine self-administration in humans: Lack of evidence for loading and maintenance phases. Pharmacology Biochemistry And Behavior 2009, 95: 51-55. PMID: 20005893, PMCID: PMC2824073, DOI: 10.1016/j.pbb.2009.12.005.
- Youssef N, Angarita G. Dialectical Behavior Therapy with Suicidal Adolescents. Annals Of Clinical Psychiatry 2008, 20: 244-245. DOI: 10.1080/10401230802362704.
- Loebl T, Angarita G, Pachas G, Huang K, Lee S, Nino J, Logvinenko T, Culhane M, Evins A. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. The Journal Of Clinical Psychiatry 2008, 69: 480-6. PMID: 18294021, DOI: 10.4088/jcp.v69n0321.
- Angarita G, Reif S, Pirard S, Lee S, Sharon E, Gastfriend D. No-Show for Treatment in Substance Abuse Patients with Comorbid Symptomatology: Validity Results from a Controlled Trial of the ASAM Patient Placement Criteria. Journal Of Addiction Medicine 2007, 1: 79-87. PMID: 21768939, DOI: 10.1097/adm.0b013e3180634c1d.
- Pirard S, Sharon E, Kang S, Angarita G, Gastfriend D. Prevalence of physical and sexual abuse among substance abuse patients and impact on treatment outcomes. Drug And Alcohol Dependence 2004, 78: 57-64. PMID: 15769558, DOI: 10.1016/j.drugalcdep.2004.09.005.